Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer’s Disease (NICE)

[A version of this abstract appears in: Dementia: the Latest Evidence Newsletter (RWHT), Volume 1 Issue 9, April 2011].

Abstract

Note: The long-awaited review and re-appraisal of Donepezil, Galantamine, Rivastigmine and Memantine for the treatment of Alzheimer’s Disease has resulted in changes to previous guidance.

The three acetylcholinesterase (AChE) inhibitors; Donepezil, Galantamine and Rivastigmine are now recommended as options for managing mild as well as moderate Alzheimer’s disease.

Memantine is now recommended as an option for managing moderate Alzheimer’s Disease for people who cannot take AChE inhibitors, and is also an option for managing severe Alzheimer’s disease.

Note: These updates have also been reflected in the main NICE-SCIE Dementia Guideline.

Quotation:

“Only specialists in the care of patients with dementia (that is, psychiatrists including those specialising in learning disability, neurologists, and physicians specialising in the care of older people) should initiate treatment. Carers’ views on the patient’s condition at baseline should be sought.

Treatment should be continued only when it is considered to be having a worthwhile effect on cognitive, global, functional or behavioural symptoms.

Patients who continue on treatment should be reviewed regularly using cognitive, global, functional and behavioural assessment. Treatment should be reviewed by an appropriate specialist team, unless there are locally agreed protocols for shared care. Carers’ views on the patient’s condition at follow-up should be sought”.

Full Text Link

Reference

National Institute for Health and Clinical Excellence, (2011). NICE Technology Appraisal Guidance TA217. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (review of NICE technology appraisal guidance 111). London: NICE, March 23rd 2011.

About Dementia and Elderly Care News

Dementia and Elderly Care News. Wolverhampton Medical Institute: WMI. (jh)
This entry was posted in Acute Hospitals, Community Care, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), Guidelines, Management of Condition, National, NICE Guidelines, Pharmacological Treatments, Practical Advice, Systematic Reviews, Universal Interest and tagged , , , , , , , , , , , , , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.